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ABSTRACT
Natural products play a significant role in drug dis-
covery and development. Many topological phar-
macophore patterns are common between natu-
ral products and commercial drugs. A better un-
derstanding of the specific physicochemical and
structural features of natural products is important
for corresponding drug development. Several ency-
clopedias of natural compounds have been com-
posed, but the information remains scattered or
not freely available. The first version of the Super-
natural database containing ∼50 000 compounds
was published in 2006 to face these challenges.
Here we present a new, updated and expanded ver-
sion of natural product database, Super Natural II
(http://bioinformatics.charite.de/supernatural), com-
prising ∼326 000 molecules. It provides all corre-
sponding 2D structures, the most important struc-
tural and physicochemical properties, the predicted
toxicity class for ∼170 000 compounds and the ven-
dor information for the vast majority of compounds.
The new version allows a template-based search for
similar compounds as well as a search for compound
names, vendors, specific physical properties or any
substructures. Super Natural II also provides infor-
mation about the pathways associated with synthe-
sis and degradation of the natural products, as well
as their mechanism of action with respect to struc-
turally similar drugs and their target proteins.
INTRODUCTION
Natural products (NPs) are classical starting points for drug
discovery. All herbal-based medicines are derived from nat-
ural compounds (1). NPs were involved in the develop-
ment of ∼64% of all drugs (2). For instance, easily avail-
able drugs such as lovastatin, paclitaxel, penicillin and sili-
binin were either directly or indirectly derived from NPs.
NPs are an invaluable source of inspiration for organic
chemists to synthesize novel drug candidates (3–6). Macro-
cycles, ring structures with more than 12 atoms, are a typ-
ical structural feature of natural compounds. They help to
organize the overall molecule structure such that key func-
tional groups can specifically interact with binding sites
of target molecules such as proteins, resulting in few or
no entropic loss on binding. Often macrocyclic NPs such
as erythromycin, rapamycin, tacrolimus possess favorable
drug-like physicochemical and pharmacokinetic properties
like lipophilicity, metabolic stability, increased solubility
and bioavailability (7). Such properties are important for
protein–protein interaction targets (8). It is known that
more NP-like molecules are needed for corresponding li-
brary design of the pharmaceutical industry (9,10). An in-
teresting example for NP-based drugs starts with camp-
tothecin isolated from the bark and stem of Camptotheca
acuminata (11), which inhibits the DNA enzyme topoiso-
merase I. Because of low solubility and high adverse drug
reaction during clinical trials (12), it was modified to the
analogs topotecan and irinitecan (13). These analogs have
been approved for cancer chemotherapy. The availability of
NP databases is important for in silico screening in drug dis-
covery. However, NP databases, such as the Dictionary of
Natural Products (http://dnp.chemnetbase.com) and Natu-
ral Product Alert (14), are often commercial or freely avail-
able only with restricted information.
Better knowledge of the anabolism and catabolism of
NPs leads to a relevant understanding of their ecological
role. Often, primary metabolic pathways are single prod-
uct and target-oriented (like tryptophan is synthesized in
the tryptophan pathway, cholesterol is synthesized in the
cholesterol pathway), whereas the pathways of the sec-
ondarymetabolism are diversity-oriented, resulting inmore
than one product (15). This unique chemical diversity of
secondary metabolites is one of the reasons for the continu-
ing scientific interest inNPs (16,17,18). Nature has designed
and selected secondary metabolites for different purposes.
They often act as ‘defense compounds’ and were optimized
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during evolution for specific interactions with biological re-
ceptors (15,16).
Some NPs are toxic and produce adverse effects on cells
or the whole organism. For instance, consumption of alpha-
amanitin, a toxic peptide produced byAmanitamushrooms
(19), can lead to irreversible kidney and liver damage (20).
This NPmolecule is considered as one of the deadliest com-
pounds known.
Super Natural II is a freely available, web-based and easy
to access database of NPs. Super Natural II contains a lot
of information for each compound, includingNP class, pre-
dicted toxicity class, mechanism of action (MoA) and path-
ways information. Super Natural II provides possible tox-
icity alert for the use of a particular natural compound.
However, the absence of such toxicity prediction or alert
for a compound should not be taken as an indication of
safety. The toxicity prediction for the database compounds
is based on their structural similarity to the known toxic
compounds, calculated using ProTox (21). ProTox shows
good performance in comparison to other commercial and
free toxicity prediction methods.
To the best of our knowledge, Super Natural II is the first
publicly available database of natural compounds with as
many as 326 000 molecules and the corresponding wealth
of additional information. Super Natural II provides infor-
mation on MoA, pathways information and toxicity infor-
mation integrated into one single platform. A comparison
of Super Natural II to other NP databases is provided in
Supplementary Table S1.
MATERIALS AND METHODS
The Super Natural II database contains ∼326 000 unique
compounds, collected from 16 suppliers (as listed on the Su-
per Natural II website) and five freely available databases
(22–26).
Data preparation
The collected raw data from 21 sources were standardized
using the chemoinformatic pipeline of the Konstanz Infor-
mation Miner (KNIME) (27) (Steps 2–5) and ChemAxon
(http://www.chemaxon.com). (Step 1): (1) standardizing
files into the structure-data (SD) format, using JChem. In
this process, incomplete structures were deleted, charges
normalized and ions and smaller parts (e.g. water, salts)
removed. (2) Reading standardized SD files, (3) generat-
ing InChIKeys (RDKit to InChi), (4) removing duplicates
and (5) writing new SD files (see Supplementary Figure
S3). Corresponding supplier information is mapped to each
unique structure. The compounds are listed in the final
database with a unique identifier (SN ID). The 2D struc-
ture of each compound provided by the suppliers was used
to generate 3D structures (Discovery studio, Accelrys Inc.,
http://www.accelrys.com/dstudio). A set of physicochemical
descriptors such asmolecular weight, logP, H-bond donors,
H-bond acceptors, number of rings, aromatic rings, number
of bonds and the number of heavy atoms was computed
for each compound using JChem 6.1.3 (November 2013),
ChemAxon (http://www.chemaxon.com).
Similarity search and substructure search
The structural similarity search was implemented using
Open Babel (28). The Tanimoto coefficient (29) is used
to measure the 2D similarity. It compares the structural
similarity between the query molecule and the database
entries using a concatenated fingerprint of the ‘FP2’ and
‘FP4’ Open Babel fingerprints calculated byMychem (http:
//mychem.sourceforge.net). The Tanimoto coefficient is a
number between 0 and 1 (1 corresponding to ‘maximum
similarity’) (30). Pre-calculated fingerprints for all database
entries are stored as blob objects in the MySQL-database.
For a query structure it is calculated during the search. The
top 15 results are returned.
For the substructure search, a fast-search index for all
database compounds was created using Open Babel (28).
The computed index is then queried by Simplified Molecu-
lar Input Line Entry Specification (SMILES) (31); resulting
in up to 4000 hits per substructure search.
Classification
Due to the greater structural diversity of NPs compared
to synthetic compounds, an increased therapeutic spectrum
can be covered (32).Different classification schemes forNPs
exist; Super Natural II has implemented a classification by
structural characteristics such as alkaloid, amino acid or
fatty acid.
Toxicity prediction
The toxicity class for each compound in the database was
calculated using ProTox (21). The toxicity is categorized
into six classes (ranging from classes I to VI) based on the
lethal dose (LD50) values in mg/kg body weight in rodents.
The toxicity class is predicted for∼170 000 compounds; for
unpredicted compounds (out of prediction range) the class
is displayed as zero. For a better understanding of the toxi-
city prediction a link to the ProTox web server is provided.
The number of NPs predicted for each toxicity class is re-
ported in Supplementary Table S2.
Mechanism of action
Drug–target relations were taken from SuperTarget (33),
which comprises >195 000 pharmacologically active com-
pounds for which interactions are quantitatively known.
These drugs were compared to all the SuperNatural II com-
pounds using a Tanimoto coefficient of 0.8 and above; the
corresponding information was stored. Each NP was then
mapped to its predicted target using the information from
the drug-NP similarity mapping. It is generally accepted
that structurally similar compounds have usually similar
biological properties (34). The target prediction was com-
puted using SuperPred web server (35), which has a predic-
tion accuracy of 75.1%. Not all the NPs are yet assigned
to a target, so similarity of a query NP to a ligand with
known receptor association(s) may provide useful insight.
For instance, search with target ‘Bcl-2’ and ‘Apoptosis reg-
ulator Bcl-2’ results in a list of drugs (15 hits) that are acting
on this specific target. This drug could be a natural com-
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pathway information on the results page, more specific facts
on the pathways involved (such as Apoptosis, Alzheimer’s
disease) and corresponding species information can also be
obtained.
Pathways
Considering information from KEGG (22) pathways of-
ten helps to better understand a specific NP–target protein
interaction. In order to display pathway maps, NPs were
mapped to potential targets with respect to their similarity
to the reference drugs (see ‘mechanism of action’ section).
For instance, given a search for the organism ‘Homo sapi-
ens’ and the pathway ‘Apoptosis’, the result page will dis-
play the corresponding pathwaymapwith all known targets
highlighted. A cursor-over on the target will display drugs
acting on the target (up to 15 hits), together with similar
NPs and related similarity score. Currently, the database is
featuring all Homo sapiens pathways, as well as pathways
from bacteria and fungi.
Clustering
A compound clustering based on structural similarity using
Tanimoto coefficients was performed for the entire data set.
The clustering was generated using an algorithm based on
DBSCAN (density-based spatial clustering of application
with noise) (37). The structural similarity clustering was
calculated using similarity measures based on the concate-
nated Open Babel FP24 fingerprint, calculated using My-
chem (http://mychem.sourceforge.net). The clustering was
based on the corresponding similarity matrix with Tani-
moto coefficient entries of 0.8 and above. The clustering is
an effective tool to compare structural similarities between
a large set of natural compounds. It results in∼27 000 clus-
ters with a minimum size of four compounds. Larger clus-
ters are broken down into smaller subsets, containing at
most 30 compounds in order to simplify the interpretation
of the complex clustering results. The clustering results are
visualized in an interactive heat map where red color corre-
sponds to high similarity and light colors to low. A cursor-
over on the heat map helps to view the corresponding com-
pound structures.
Server, database and system requirements
Super Natural II is based on a relational MySQL database
(http://www.mysql.com). To handle the chemical informa-
tion within the database, the MyChem package (http://
mychem.sourceforge.net/) is used. For most of its func-
tions, MyChem relies on the Open Babel toolbox (http:
//openbabel.org). The Super Natural II website is built
using PHP (http://www.php.net/), JavaScript (http://www.
java.com/), Ajax; web access is enabled via an Apache
HTTP Server (http://http.apache.org/). The site is best
viewed in Mozilla Firefox and also functional on alternate
browsers like Google Chrome and Microsoft Internet Ex-
plorer.
SEARCH OPTIONS
Natural compounds can be found in the Super Natural II
database via several search methods. A web-based search
tool is available, incorporating a molecular drawing inter-
face. Users can also search for compounds by properties,
chemical structures or by a combination of criteria. Ad-
ditionally, the integrated PubChem (38) search for a com-
pound name is implemented. The search results page shows
the main properties and the chemical structure of the com-
pound, as well as a link to download the structure file in the
Mol2 format. The web systemwas designed to allow a rapid
and detailed response to specific queries. Important search
options are as follows (Figure 1):
(i) First, a compound name or known supplier code can
be used to retrieve information from the database. To
get a subset of molecules having particular physico-
chemical properties, a search can be refined with more
options like molecular weight, logP value, hydrogen-
bond acceptor, hydrogen-bond donor and classifica-
tion. Additionally, one can also look for toxic natural
compounds using the toxicity class filter.
(ii) Using the ChemDoodle (http://www.chemdoodle.
com) sketcher, a user can build or import a molecular
structure and perform a similarity or substructure
search with compounds of the Super Natural II
database.
(iii) Substructure search can also be done by pre-defined
scaffolds via template search. Here, users can look for
compounds in the database containing specific groups
like certain amino acids, alpha sugars, beta sugars, D-
sugars, aromatic rings, bicyclical rings, fused rings, het-
erocyclic or polycyclic rings, etc.
(iv) An MoA search enables users to screen NPs for in-
formation on their putative molecular targets and cor-
responding pathways. Similarly, the user can specify
a target protein as search term (Uniprot ID/protein
name) and get information on natural compounds
which are predicted to interact with the specified tar-
get protein (see ’mechanism of action’ section).
(v) The pathway search enables users to display known
NPs and interacting protein targets associated with
any pathway map from KEGG. The pathways can be
searched by species, pathway type and function. Each
protein target interacting with an NP is highlighted in
yellow. A cursor-over option shows detailed informa-
tion on similar compounds.
CONCLUSION
The Super Natural II database is a freely available re-
source with different embedded search functions. It allows
a simple access to the growing number of available natu-
ral compounds. The compounds of the database comprise
a rich chemical diversity and a wide spectrum of biological
and pharmacological activities. Associated pathways and
known and predicted mechanisms of action supply addi-
tional information. We expect that Super Natural II will be
useful for studies involving virtual screening, metabolomics
and the design of new compounds. The information pro-
vided by Super Natural II about structures and physico-











D938 Nucleic Acids Research, 2015, Vol. 43, Database issue
Figure 1. Super Natural II database search options. The compound search (blue arrow) enable search via compound name, supplier, molecular weight,
logP, hydrogen-bond donor and acceptor, classifications, toxicity class as well as compounds that are purchasable. Template search (green arrow) allows
searching via a pre-defined template. MoA search (purple arrow) can be performed for a molecule structure or a target name; clusters (orange arrow) can
be searched via name, SNID (unique identifier for the Super Natural II database), IUPAC name or SMILES. All search results contain information about
physicochemical properties, toxicity class, vendor and pathway. Cluster results are displayed using heat maps and related similarity values for compounds
of the cluster. Pathway information (red arrow) can be obtained for specific species and pathway. Additionally, the molecule structure is shown.
AVAILABILITY
Super Natural II is available through the website without
registration: http://bioinformatics.charite.de/supernatural.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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